Bullish Case: HALO's ENHANZE royalty engine keeps compounding: Q2 royalties hit $308M (+50%) with raised 2026 guidance, and calls traded 94% more volume than puts. The Helium density peaks near $105-110 with a fat right shoulder to $115+, Helium's bullish risk runs 32% above bearish, and the term structure is flat-to-upward (35.6→37.1) — no stress premium priced. Momentum, cheap valuation (~11x P/E), and licensing optionality support a grind toward $120.

Bearish Case: At $109.86 HALO is up 59% YoY with a 26.6 price-to-book — any royalty ramp deceleration or guidance trim triggers sharp de-rating. The surface still prices left-tail (deep-put IV 90-240% at low strikes), the return surface includes -25% to -34% bands, and the $1.3B convertible adds debt/dilution. Market density puts real mass at $95-105, not $130+. Post-run consolidation risk is elevated after +32% in 60 days.

Potential Outcomes: 1) Rangebound $100-120 into Q3 print (35%): flat month action, IV ~36 holds.
2) Q3 beat/raise → $118-128 (25%): call flow persists, Helium density right tail realizes.
3) New ENHANZE/licensing deal → >25% rerate toward $130+ (10%): mirrors prior Merck/Vertex pattern.
4) Royalty/guidance miss → $90-100 (20%): put skew steepens first.
5) Patent/legal or macro shock → <$90 (10%): deep-put IV already prices this tail.
Calibration note: prior 'range' calls (42-48%) proved right until the Aug-Sep rerate; the Sep 1 bullish call (+15-25%) caught the move to $110 — tilt now neutral-positive.

October 03, 2026